Popular terms

Neoplasm topics
Autoimmune Disease
Autoimmune
Immune Disease
Neurotoxin
Graft Versus Host Disease
Botulinum Toxin
Modulation
Human Papillomavirus
Antibodies
Ascorbic Acid
Neoplastic
Proliferative
Epithelial
Neuroblastoma
Osteosarcoma

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Neoplasm patents



      

This page is updated frequently with new Neoplasm-related patent applications.




Date/App# patent app List of recent Neoplasm-related patents
06/23/16
20160175341 
 Hydroxyalkyl starch for the treatment of hematological neoplasms patent thumbnailHydroxyalkyl starch for the treatment of hematological neoplasms
The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (mw) above 20 and below 1300 kda and a molar substitution (ms) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.. .

06/23/16
20160175293 
 Pim kinase inhibitor combinations patent thumbnailPim kinase inhibitor combinations
The present invention relates to a pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a jak inhibitor compound, (b) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human..

06/09/16
20160160263 
 Personalized protease assay to measure protease activity in neoplasms patent thumbnailPersonalized protease assay to measure protease activity in neoplasms
Disclosed herein, the invention pertains to methods and compositions that find use in diagnostic, prognostic and characterization of neoplasia samples based on the ability of a neoplasia sample to cleave a mts molecule of the present invention. In some embodiments, a mts molecule disclosed herein has the formula (a-x-b-c), wherein a is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; b is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; x is a linker; and c is a detectable moiety..
The Regents Of The University Of California


05/19/16
20160139132 
 Method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm patent thumbnailMethod of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression of cavcolin-1, cavcolin-2, vimentin, calponon2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, ef-i-delta, or m2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.. .
Thomas Jefferson University


05/19/16
20160137646 
 Novel compounds and uses thereof patent thumbnailNovel compounds and uses thereof
The present invention provides novel compounds of any one of formulae (i)-(iv), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of formulae (i)-(iv) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


05/12/16
20160130664 
 Determining tumor load and biallelic mutation in patients with calr mutation using peripheral blood plasma patent thumbnailDetermining tumor load and biallelic mutation in patients with calr mutation using peripheral blood plasma
Compositions and fragment length analysis methods are provided for detecting calr mutations and determining tumor load in patients with myeloproliferative neoplasms.. .
Neogenomics Laboratories, Inc.


05/12/16
20160130657 
 Method of diagnosing neoplasms patent thumbnailMethod of diagnosing neoplasms
The present invention relates generally to a nucleic acid molecule, the rna and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a large intestine neoplasm. More particularly, the present invention is directed to a nucleic acid molecule, the expression profiles of which are indicative of the onset and/or progression of a colorectal neoplasm, such as an adenoma or an adenocarcinoma.
Commonwealth Scientific And Industrial Research Organisation


05/05/16
20160123982 
 Methods for assaying jak2 activity in red blood cells and uses thereof patent thumbnailMethods for assaying jak2 activity in red blood cells and uses thereof
The present invention relates to methods for assaying jak2 activity in a red blood cell. The present invention also relates to methods for diagnosing myeloproliferative neoplasm..
Universite Des Antilles Et De La Guyane


05/05/16
20160122430 
 Anti-cs1 antibodies and antibody drug conjugates patent thumbnailAnti-cs1 antibodies and antibody drug conjugates
The present disclosure provides antibodies and antibody drug conjugates that bind human cs1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.. .
Abbvie Biotherapeutics Inc.


05/05/16
20160122323 
 Inhibitors of cyclin-dependent kinase 7 (cdk7) patent thumbnailInhibitors of cyclin-dependent kinase 7 (cdk7)
The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


04/28/16
20160113958 

Modulators of adp-dependent glucokinase (adpgk) and glycerol-3-phosphate dehydrogenase (gpd2) for therapy


Described are compounds capable of modulating (a) the biological activity of adp-dependent glucokinase (adpgk) and/or glycerol-3-phosphate dehydrogenase (gpd2) or (b) the expression of the gene encoding adpgk or gpd2 for use in treating a disease (a) associated with aberrant cell proliferation, e.g., a neoplasm, or (b) of the immune system, e.g., an autoimmune disease.. .
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Recht


03/31/16
20160090634 

Detecting cholangiocarcinoma


Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting neoplasms such as cholangiocarinoma.. .
Mayo Foundation For Medical Education And Research


03/24/16
20160083803 

Methods and materials for detecting colorectal neoplasm


The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human dna, tumor assoicated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal..
Mayo Foundation For Medical Education And Research


03/17/16
20160078613 

Method and system for determining a phenotype of a neoplasm in a human or animal body


The present invention relates to a decision support system and an image analysis method for providing information for enabling determination of a phenotype of a neoplasm in a human or animal body for enabling prognostication, comprising the steps of: receiving, by a processing unit, image data of the neoplasm; and deriving, by the processing unit, a plurality of image feature parameter values from the image data, said image parameter values relating to image features associated with the neoplasm; and deriving, by said processing unit using a signature model, one or more neoplasm signature model values associated with the neoplasm from said image feature parameter values, wherein said signature model includes a functional relation between or characteristic values of said image feature parameter values for deriving said neoplasm signature model values. .
Stichting Maastricht Radiation Oncology "maastro-clinic"


03/17/16
20160076106 

Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm


Methods are provided for diagnosing, detecting, or prognosticating a gep-nen based on the expression level score of biomarkers exhibiting differential expression in subjects having a gep-nen relative to a reference or control sample. The invention also provides compositions and kits comprising these biomarkers and methods of using these biomarkers in subsets or panels thereof to diagnose, classify, and monitor gep-nen and types of gep-nen.
Clifton Life Sciences Llc


03/10/16
20160067198 

Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use in devitalizing external and internal neoplasms


Halogenated aliphatic carboxylic acids, salts and/or oligomers or polymers thereof, which exhibit a devitalizing effect of neoplastic tissues, are disclosed. Methods and uses that utilize these compounds for the treatment of medical conditions associated with a neoplastic tissue are also disclosed.
Cimas Limited


03/03/16
20160060264 

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


03/03/16
20160058859 

Immunogenic complex for vaccination and the production thereof


The present invention is related to an immunogenic complex comprising a polymerized antigen, mannan and a dialdehyde, the composition comprising it and the use thereof as an immune response stimulator and vaccine, useful in the treatment of infectious diseases, neoplasms and allergies. Likewise, the invention relates to the method for obtaining said immunogenic complex, based on the antigen and mannan simultaneous polymerization and conjugation by using a dialdehyde..
Inmunotek, S.l.


02/18/16
20160046661 

Ras inhibitors and uses thereof


Described herein are compounds of formulae (i)-(ii), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject..
Dana-farber Cancer Institute, Inc.


02/18/16
20160046561 

Substituted tetracycline compounds


The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms..
Paratek Pharmaceuticals, Inc.


02/11/16
20160040246 

Detecting neoplasm


Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer. Accordingly, provided herein is technology for pancreatic cancer screening markers and other gastrointestinal cancer screening markers that provide a high signalto-noise ratio and a low background level when detected from samples taken from a subject (e.g., stool sample).
Exact Sciences Corporation


02/04/16
20160033510 

Antibodies for the identification of pancreatic disorders


Levels of vegf-a, vegf-c and pge2 were measured in patient groups presenting with different types of pancreatic lesions. Pancreatic fluids that exhibited high levels of vegf-a and relative low levels of vegf-c correlated well with a diagnosis of serous cystadenoma.
Indiana University Research And Technology Corp.


02/04/16
20160031802 

3, 10, and 12a substituted tetracycline compounds


The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression..
Paratek Pharmaceuticals, Inc.


01/21/16
20160018398 

Compositions and methods for detecting oral neoplasm


Methods and kits for assessing the presence of, and for detecting cancer, notably oral cancer, are disclosed. Such methods and kits use one or more lectins operably linked to a fluorophore, wherein the lectin binds differentially to cancerous and non-cancerous tissues, and wherein the fluorophore facilitates visualizing the differential binding.
Inter-med, Inc.


01/14/16
20160008467 

Method for the production of sub-micrometric particles and their theranostic use in oncology with a specific apparatus


The invention relates to a method for producing sub-micrometric particles, which comprises: mechanochemical treatment of homogeneous or heterogeneous magnetic materials until a mass which consists mostly of magnetic nanocrystal aggregates is obtained; selection of aggregates so that the nanocrystals have a curie temperature within a predefined variation range; functionalization of the aggregates in order to obtain coating thereof with molecules of one or more of the following types of substances: substances for which the tumour cells have a particular metabolic avidity; substances having a biochemical affinity with the tumour cells; substances having an affinity with the acid microenvironment which surrounds the neoplastic cells. In addition to the method the following are claimed: the particles thus produced; their theranostic use which allows the in vivo execution, without interruption, of the diagnosis or monitoring step and the therapy step by means of magnetic hyperthermia of malignant neoplasms, including those localized in the so-called “sanctuary sites” such as the central nervous system and the testicle; an apparatus designed for this use..
Mbn Nanomaterialia Spa


12/31/15
20150374656 

Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

12/31/15
20150374648 

Compositions and methods of use of phorbol esters in the treatment of neoplasms


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease.

12/24/15
20150368260 

Amino-substituted isothiazoles


The present invention relates to isothiazoles of general formula (i) which inhibit the mitotic checkpoint: in which a, r1 and r2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.. .
Bayer Pharma Aktiengesellschaft


12/24/15
20150366867 

Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator


This invention provides a method of treating a subject suffering from atherosclerosis or a myeloproliferative neoplasm which comprises administering to the subject an amount of a lyn kinase activator effective to activate lyn kinase so as to thereby treat the subject.. .

12/10/15
20150354013 

Detecting neoplasm


This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided..
Mayo Foundation For Medical Education And Research


12/03/15
20150346191 

Compositions and methods for prognosis and treatment of neoplasm


A protocol for assessing the prognosis for a patient diagnosed with a neoplasm or suspected of having a neoplasm is provided herein. The protocol involves the steps of determining a mitotic cells to proliferating cells ratio (m:p ratio) in a neoplastic tissue sample obtained from the patient and producing a prognosis for the neoplasm based on the m:p ratio..
Novazoi Theranostics, Inc.


12/03/15
20150342982 

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms


Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have myeloproliferative disorders, such as essential thrombocythemia (et). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having myeloproliferative disorders, such as et..
Geron Corporation


11/19/15
20150328216 

Indole compounds for use in treating inflammation and cancer


Provided herein are compounds, comprising formula (i) or formula (ii), and their pharmaceutically acceptable salts. Also provided are pharmaceutical compositions comprising a pharmaceutically acceptable excipient and at least one compound of formula (i) and (ii), singly or in combination with other pharmaceutically active ingredients, such as anti-inflammatory agents or anticancer agents.
Board Of Trustees Of The University Of Arkansas


10/22/15
20150299115 

Therapeutic compounds and compositions


Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (idh 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Agios Pharmaceuticals, Inc


10/15/15
20150292032 

Treatment of cancer by targeting quiescent cancer cells


A method for treating a subject suffering from a neoplasm, comprising determining the expression level of a dyrk1 selected from dyrk1a or dyrk1b within a cell population in a sample of neoplastic cells and determining the quiescent state of these cells, and if the dyrk1 is expressed in the sample then administering an effective amount of a modulator of dyrk1 activity, either alone or as a part of a combination therapy.. .

10/15/15
20150291609 

Mertk-specific pyrimidine compounds


The present invention includes pyrimidine compounds that selectively inhibit mer tyrosine kinase (mertk) activity and/or tyro3 tyrosine kinase activity, and use of these pyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .

10/15/15
20150291606 

Mertk-specific pyrrolopyrimidine compounds


The present invention includes pyrrolopyrimidine compounds that selectively inhibit mer tyrosine kinase (mertk) activity and/or tyro3 tyrosine kinase activity, and use of these pyrrolopyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .

10/15/15
20150291605 

Mertk-specific pyrazolopyrimidine compounds


The present invention includes pyrazolopyrimidine compounds of formula i that selectively inhibit mer tyrosine kinase (mertk) activity and/or tyro3 tyrosine kinase activity, and use of these pyrazolopyrimidine compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .

10/15/15
20150290212 

Therapeutic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity


Pyrazolopyrimidine compounds, methods of use, and processes for making compounds with anti-mer tyrosine kinase activity comprising formula i, ii, iii, iv, or a pharmaceutically acceptable composition, salt, isotopic analog, or prodrug thereof, are provided. The pyrazolopyrimidine compounds described herein have mer tyrosine kinase (mertk) inhibitory activity and are useful as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against mertk −/− tumors and itd and tkd mutant forms of acute myeloid leukemia (aml)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms..

10/15/15
20150290197 

Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity


Uses of pyrrolopyrimidines with anti-mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against mertk−/− tumors and itd and tkd mutant forms of acute myeloid leukemia (aml)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .

10/15/15
20150290194 

Therapeutic uses of selected pyrimidine compounds with anti-mer tyrosine kinase activity


Uses of pyrimidines with anti-mer tyrosine kinase activity as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against mertk −/− tumors and itd and tkd mutant forms of acute myeloid leukemia (aml)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.. .

10/08/15
20150284688 

Diffusible factors and cancer cells


The present invention relates to modified cancer cells that are defective in the production of diffusible factors (e.g., growth factors), and to the use of such cells for impairing the growth of a population of human cells, in particular wherein the cells are human cancer cells and the population of cells is a neoplasm, tumour or cancer. The invention preferably comprises the step of modifying tumour cells by deleting or modifying endogenous genes that code for (or affect the production of), diffusible growth factors that promote cell survival and proliferation..

10/01/15
20150275314 

Detecting colorectal neoplasm


Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as colorectal cancer.. .
Exact Sciences Corporation


09/24/15
20150266888 

Derivatives of camptothecin, a producing them and their use


The subject of the present invention are water-soluble derivatives of camptothecin, their synthesis and use. These compounds exhibit preferable biological properties for use in anti-neoplasm therapy..
Instytut Chemii Organicznej Polskiej Akademii Nauk


09/24/15
20150265635 

9-substituted minocycline compounds


The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression..
Paratek Pharmaceuticals, Inc.


09/03/15
20150247204 

Differential diagnosis of hepatic neoplasms


Methods for making a differential diagnosis of hepatic neoplasms, e.g., tumors, and for identifying metastatic tumors of hepatic origin, based on detection of levels of albumin mrna. The methods can also be used to select treatments or guide treatment decisions..
Affymetrix, Inc.


09/03/15
20150246913 

Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the compounds of formula (i) or (ii), or compositions thereof, for treating or preventing a wide range of diseases (e.g., proliferative diseases (e.g., cancers, benign neoplasms, angiogenesis, inflammatory diseases, autoimmune diseases) and metabolic diseases (e.g., diabetes (e.g., type 2 diabetes, gestational diabetes)) in a subject.
Beth Israel Deaconess Medical Center, Inc.


09/03/15
20150246064 

Method for treating hematopoietic neoplasms


This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ros) in vivo. The method may further comprise co-administering a second chemotherapeutic agent..

08/20/15
20150231167 

Treatment of hematological neoplasms


Hematological neoplasms resistant to treatment with an atp-competitive inhibitor of bcr-abl are treated by administration of n6-benzyladenosine, n6-benzyladenosine-5′-monophosphate, or pharmaceutically acceptable salts thereof.. .
Thomas Jefferson University


08/13/15
20150225438 

Suprametallogels and uses thereof


The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology


07/30/15
20150209379 

Treatment of prostate cancer and hematologic neoplasms


Prostate cancer and hematological neoplasms are treated by administration of (i) a compound of formula i: wherein: r1 is —oh or —o—p(o)(oh)2; and r2 is (ii) or (iii); (ii) n6-benzyladenosine, (iii) n-(phenylmethyl)-7-β-d-ribofuranosyl-7h-pyrrolo [2,3 -d]pyrimidin-4-amine, (iv) n-(phenylmethyl)-7β-d-ribofuranosyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine 5′-monophosphate; or a pharmaceutically acceptable salt thereof.. .
Thomas Jefferson University


07/23/15
20150202178 

Compositions and methods of use of phorbol esters


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like hiv and aids, or the development of neoplasms in a mammalian subject.

07/23/15
20150202177 

Compositions and methods of use of phorbol esters in the treatment of neoplasms


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease.

07/09/15
20150191417 

Anti-proliferative compounds and uses thereof


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject.
The General Hospital Corporation D/b/a Massachusetts General Hospital


06/18/15
20150166558 

Gonadotropin releasing hormone receptor antagonists, the preparation thereof and pharmaceutical composition comprising the same


Disclosed are a gonadotropin releasing hormone receptor antagonist and a pharmaceutical composition including the same, which can be useful in preventing or treating a sex hormone-related disease such as endometriosis, amenorrhea, irregular menstruation, uterine myoma, uterine fibroids, polycystic ovarian disease, lupus erythematous, hypertrichosis, precocious puberty, short stature, acne, alopecia, gonadal steroid-dependent neoplasms, gonadotropin-producing pituitary adenoma, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hyperplasia, contraception, and infertility, as well as alzheimer disease.. .
Sk Chemicals Co., Ltd.


06/11/15
20150159223 

Method of diagnosing neoplasms


The present invention relates generally to nucleic acid molecules, the rna and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma.
Commonwealth Scientific And Industrial Research Organisation


06/04/15
20150152505 

Method of screening for colorectal cancer


The present invention relates generally to a method of determining one or more probabilities of respective classifications of a neoplasm into one or more neoplastic categories. More particularly, the present invention relates to a method of determining the probability of classification of a large intestine neoplasm into one or more categories selected from adenoma, stage i, stage ii, stage iii or stage iv by screening for changes to the methylation levels of a panel of gene markers, including bcat1, ikzf1, irf4, grasp and/or cahm.
Clinical Genomics Pty. Ltd.


06/04/15
20150152422 

Mirnas as therapeutic targets in cancer


Micrornas (mirnas) are a class of non-coding small rna molecules that regulate gene expression at the post-transcriptional level by interacting with 3′ untranslated regions (utrs) of their target mrnas. The invention relates to the application of mir-192 and mir-215.
The Research Foundation For The State University Of New York


05/28/15
20150148345 

Therapies for treating myeloproliferative disorders


Provided herein are methods, compositions, and kits for treating myeloproliferative disorders or neoplasms, including polycythemia vera, primary myelofibrosis, thrombocythemia, and essential thrombocythemia.. .
Gilead Sciences, Inc.


05/21/15
20150141275 

Diagnostic gene marker panel for colorectal cancer


The present invention relates generally to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention relates to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for changes to the methylation levels of a panel of gene markers including bcat1, ikzf1, irf4, grasp and/or cahm.
Commonwealth Scientific And Industrial Research Organisation


05/07/15
20150125868 

Asxl1 as a new diagnostic marker of myeloid neoplasms


The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the asxl1 (additional sex combs like 1) gene coding for the polypeptide having the sequence seq id no 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method..
Inserm (institut National De La Santé Et De La Recherche Médicale)


04/30/15
20150119350 

Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms


Disclosed herein are methods for detecting, diagnosing and/or prognosing a malignant adrenocortical tumor. Also disclosed are methods of treating a malignant adrenocortical tumor, such as acc.
The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services


04/23/15
20150110804 

Compositions and methods for treating b-lymphoid malignancies


Compositions and methods for inhibiting, treating, and/or preventing a b-cell neoplasm are provided.. .
The Trustees Of The University Of Pennsylvania


04/16/15
20150105355 

4-dedimethylamino tetracycline compounds


The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression..
Paratek Pharmaceuticals, Inc.


03/19/15
20150079595 

Methods and materials for detecting gene amplification


This document relates to methods and materials involved in detecting gene amplification in a mammal. For example, methods and materials for detecting amplification at cpm and mdm2 loci to determine the presence or absence of a malignant lipomatous neoplasm in a mammal are provided..
Mayo Foundation For Medical Education And Research


03/12/15
20150072986 

Urea derivatives and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


03/12/15
20150072960 

Compositions and methods of use of phorbol esters in the treatment of neoplasms


Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease.
Biosuccess Biotech Co. Ltd.


03/12/15
20150072947 

Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers


The present invention uses methylomic analysis and discovers dna methylation biomarkers for prediction of ovarian cancer prognosis and detection of malignant ovarian cancer. In addition to being independent prognostic factors for patients with current treatment protocols, these dna methylations are important biomarkers for individualized medicine for future chemotherapy (especially the demethylation agents or other epigenetic drugs)..
National Defense Medical Center


03/05/15
20150065946 

Therapeutic applications of calcium electroporation to effectively induce tumor necrosis


The present inventors have shown that electroporation with calcium ions are efficient on cutaneous and subcutaneous nodules. In particular the present inventors here disclose that a solution comprising calcium ions (ca2+) with a concentration of at least 0.1 m is extremely useful in a method of treating a neoplasm, such as cancer with means for causing transient permeabilisation of the cell membranes of at least part of the neoplasm before, during and/or after administration of said solution, wherein said solution is administered with a ratio of 0.2 to 0.8 of the volume of said part of the neoplasm..
Aarhus Universitet


03/05/15
20150065456 

Agent for treatment and prevention of cancer


The invention provides methods of treating or preventing in a subject a cancer, tumor, or neoplasm, including malignancies or metastases thereof, using a direct factor xa inhibitor. The methods particularly involve the treatment of human patients afflicted with a malignant cancer, tumor, or neoplasm with an effective amount of the factor xa inhibitor.
Daiichi Sankyo Company, Limited


03/05/15
20150065352 

Monitoring health and disease status using clonotype profiles


There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Sequenta, Inc.


02/26/15
20150057297 

Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions


The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, t-cell neoplasms, and cosmetic conditions..
The General Hospital Corporation D/b/a Massachusetts General Hospital




Neoplasm topics: Autoimmune Disease, Autoimmune, Immune Disease, Neurotoxin, Graft Versus Host Disease, Botulinum Toxin, Modulation, Human Papillomavirus, Antibodies, Ascorbic Acid, Neoplastic, Proliferative, Epithelial, Neuroblastoma, Osteosarcoma

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Neoplasm for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Neoplasm with additional patents listed. Browse our RSS directory or Search for other possible listings.


4.8817

4724

71 - 0 - 102